Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
- Citation data:
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN: 1078-0432, Vol: 21, Issue: 6, Page: 1267-72
- Publication Year:
- Medicine; Biochemistry, Genetics and Molecular Biology
- Most Recent Tweet View All Tweets